This article was originally published in The Gray Sheet
Executive SummarySubmits premarket approval application to FDA on Nov. 9 for its NMP22 test kit for detecting and monitoring bladder cancer. The kit is based on the company's nuclear matrix protein technology. Matritech plans to sell the test for $20-$30 each; "four or five tests per year could be required on patients needing frequent monitoring," the company notes. Other NMP assays in Matritech's pipeline include tests for breast, cervical, colorectal and prostate cancers
You may also be interested in...
The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.
FDA approved sNDAs from GlaxoSmithKline for diclofenac-containing Voltaren Arthritis Pain for the temporary relief of arthritis pain and from Alcon for Pataday olopatadine drops at 0.2% concentration for once-daily use temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander and 0.1% for twice-daily use for the same indications plus redness relief.